中草药

刺五加干预帕金森病非运动症状相关α-突触核蛋白病理级联的潜在机制

PDF下载

中草药 | 综述 2026,57(19): 7886-7898

收起

中草药 |综述 2026 , 57 (19) : 7886 -7898

刺五加干预帕金森病非运动症状相关α-突触核蛋白病理级联的潜在机制

全屏

作者信息

作者简介:

刘裕康: 刘裕康（2001—），男，硕士研究生，主要从事中药药性理论研究。E-mail:18745348461@163.com

Potential mechanisms of Acanthopanacis Senticosi Radix et Rhizoma seu Caulis in modulating α-synuclein pathological cascade associated with non-motor symptoms of Parkinson’s disease

Affiliations

doi: 10.7501j.issn.0253-2670.2026.19.031

文章导航

摘要

收起

帕金森病（Parkinson’s disease，PD）非运动症状涉及嗅觉减退、快速眼动睡眠行为障碍、情绪异常、认知障碍及自主神经功能紊乱等多维表现，可发生于疾病前驱期及进展期，其发生发展与α-突触核蛋白（alpha-synuclein，α-syn）异常折叠、聚集、清除障碍及朊病毒样传播密切相关。刺五加具有益气健脾、补肾安神等功效，现代药理研究显示其多成分、多靶点和多通路调节特点与α-syn病理级联的复杂性具有较高契合度。围绕α-syn病理级联，通过系统梳理α-syn生理构象动态、病理转化基础、聚集驱动因素、细胞稳态失衡及中枢神经环路损伤机制，进一步分析刺五加通过改善氧化应激、神经炎症、蛋白清除障碍、神经递质失衡及脑-肠轴异常等α-syn病理相关微环境，间接影响α-syn异常积累及非运动症状相关病理过程的潜在作用，为PD非运动症状的综合干预提供新的研究思路。

关键词

帕金森病 / 刺五加 / 非运动症状 / α-突触核蛋白 / 改善氧化应激

Abstract

收起

Non-motor symptoms of Parkinson’s disease (PD) involve multidimensional manifestations such as hyposmia, rapid eye movement sleep behavior disorder, mood disorder, cognitive impairment and autonomic nerve dysfunction, which can occur in the prodromal and progressive stages of the disease. Its occurrence and development are closely related to abnormal folding, aggregation, clearance disorder of alpha-synuclein (α-syn) and prion-like transmission. Ciwujia (Acanthopanacis Senticosi Radix et Rhizoma seu Caulis)has the effects of invigorating qi and spleen, tonifying kidney and tranquilizing mind. Modern pharmacological studies have shown that its multi-components, multi-targets and multi-pathways regulation characteristics are highly compatible with the complexity of the pathological cascade of α-syn. Focusing on the pathological cascade of α-syn, by systematically combing the physiological conformation dynamics of α-syn, the basis of pathological transformation, the driving factors of aggregation, the imbalance of cell homeostasis and the mechanism of central nervous circuit damage, the potential role of Acanthopanacis Senticosi Radix et Rhizoma seu Caulisin indirectly affecting the abnormal accumulation of α-syn and the pathological process related to non-motor symptoms by improving α-syn pathological related microenvironment such as oxidative stress, neuroinflammation, protein clearance disorder, neurotransmitter imbalance and brain-gut axis abnormality was further analyzed, which provided a new research idea for the comprehensive intervention of non-motor symptoms of PD.

Key words

Parkinson’s disease / Acanthopanacis Senticosi Radix et Rhizoma seu Caulis / non-motor symptoms / α-synuclein / alleviate oxidative stress

引用本文

刘裕康, 高鑫, 刘树民. 刺五加干预帕金森病非运动症状相关α-突触核蛋白病理级联的潜在机制. 中草药, 2026 , 57 (19) : 7886 -7898 . DOI: 10.7501j.issn.0253-2670.2026.19.031

LIU Yukang, GAO Xin, LIU Shumin. Potential mechanisms of Acanthopanacis Senticosi Radix et Rhizoma seu Caulis in modulating α-synuclein pathological cascade associated with non-motor symptoms of Parkinson’s disease[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (19) : 7886 -7898 . DOI: 10.7501j.issn.0253-2670.2026.19.031

基金

收起

黑龙江省自然科学基金项目 (PL2024H243); 中国博士后科学基金第73批面上项目 (2023M731029); 黑龙江省博士后资助面上项目 (LBH-Z22251); 黑龙江省大学生创新训练计划项目 (202410228025); 黑龙江省2026年度中医药科研课题项目 (ZHY2026-025)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Bloem B R, Okun M S, Klein C. Parkinson’s disease [J]. Lancet, 2021, 397(10291): 2284-2303.
Morimoto R, Iijima M, Okuma Y, et al. Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: A multicenter cross-sectional study [J]. Front Aging Neurosci, 2023, 15: 1252596.
Pringsheim T, Day G S, Smith D B, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: A report of the AAN guideline subcommittee [J]. Neurology, 2021, 97(20): 942-957.
Ruf W P, Meirelles J L, Danzer K M. Spreading of alpha-synuclein between different cell types [J]. Behav Brain Res, 2023, 436: 114059.
La Vitola P, Szegö E M, Pinto-Costa R, et al. Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase [J]. npj Park Dis, 2024, 10: 233.
Davydov M, Krikorian A D. Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: A closer look [J]. J Ethnopharmacol, 2000, 72(3): 345-393.
Cicero A F G, Derosa G, Brillante R, et al. Effects of Siberian ginseng (Eleutherococcus senticosus Maxim.) on elderly quality of life: A randomized clinical trial [J]. Arch Gerontol Geriatr, 2004, 38: 69-73.
Hartz A J, Bentler S, Noyes R, et al. Randomized controlled trial of Siberian ginseng for chronic fatigue [J]. Psychol Med, 2004, 34(1): 51-61.
Mahul-Mellier A L, Burtscher J, Maharjan N, et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration [J]. Proc Natl Acad Sci USA, 2020, 117(9): 4971-4982.
Calabresi P, Mechelli A, Natale G, et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction [J]. Cell Death Dis, 2023, 14(3): 176.
Wang Q, Luo Y Q, Ray Chaudhuri K, et al. The role of gut dysbiosis in Parkinson’s disease: Mechanistic insights and therapeutic options [J]. Brain, 2021, 144(9): 2571-2593.
Takahashi R, Yamakado H, Uemura N, et al. The gut-brain axis based on α-synuclein propagation: Clinical, neuropathological, and experimental evidence [J]. Int J Mol Sci, 2025, 26(9): 3994.
Sharma M, Burré J. α-Synuclein in synaptic function and dysfunction [J]. Trends Neurosci, 2023, 46(2): 153-166.
Stephens A D, Zacharopoulou M, Moons R, et al. Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity [J]. Nat Commun, 2020, 11: 2820.
Vidović M, Rikalovic M G. Alpha-synuclein aggregation pathway in Parkinson’s disease: Current status and novel therapeutic approaches [J]. Cells, 2022, 11(11): 1732.
Surguchov A, Surguchev A. Synucleins: New data on misfolding, aggregation and role in diseases [J]. Biomedicines, 2022, 10(12): 3241.
Yoo H, Lee J, Kim B, et al. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease [J]. BMB Rep, 2022, 55(7): 323-335.
Canever J B, Soares E S, de Avelar N C P, et al. Targeting α-synuclein post-translational modifications in Parkinson’s disease [J]. Behav Brain Res, 2023, 439: 114204.
Brembati V, Faustini G, Longhena F, et al. Alpha synuclein post translational modifications: Potential targets for Parkinson’s disease therapy? [J]. Front Mol Neurosci, 2023, 16: 1197853.
Zhang S J, Zhu R W, Pan B Y, et al. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein [J]. Nat Neurosci, 2023, 26(2): 213-225.
Vasili E, Dominguez-Meijide A, Flores-León M, et al. Endogenous levels of alpha-synuclein modulate seeding and aggregation in cultured cells [J]. Mol Neurobiol, 2022, 59(2): 1273-1284.
Peng C, Gathagan R J, Covell D J, et al. Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies [J]. Nature, 2018, 557(7706): 558-563.
Sato S, Uchihara T, Fukuda T, et al. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice [J]. Sci Rep, 2018, 8: 2813.
Zheng W, Fan D S. Glucocerebrosidase mutations cause mitochondrial and lysosomal dysfunction in Parkinson’s disease: Pathogenesis and therapeutic implications [J]. Front Aging Neurosci, 2022, 14: 851135.
Kim S, Kwon S H, Kam T I, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease [J]. Neuron, 2019, 103(4): 627-641.
Wu S J, Schekman R W. Intercellular transmission of alpha-synuclein [J]. Front Mol Neurosci, 2024, 17: 1470171.
Schmitt V, Masanetz R K, Weidenfeller M, et al. Gut-to-brain spreading of pathology in synucleinopathies: A focus on molecular signalling mediators [J]. Behav Brain Res, 2023, 452: 114574.
Henderson M X, Cornblath E J, Darwich A, et al. Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis [J]. Nat Neurosci, 2019, 22(8): 1248-1257.
Mazzotta G M, Conte C. Alpha synuclein toxicity and non-motor Parkinson’s [J]. Cells, 2024, 13(15): 1265.
Grass L, Grimaldi S, Damier P. Prodromal Parkinson’s disease [J]. Rev Neurol, 2025, 181(9): 863-880.
Stefani A, Antelmi E, Arnaldi D, et al. From mechanisms to future therapy: A synopsis of isolated REM sleep behavior disorder as early synuclein-related disease [J]. Mol Neurodegener, 2025, 20(1): 19.
Sobreira-Neto M A, Stelzer F G, Gitaí L L G, et al. REM sleep behavior disorder: Update on diagnosis and management [J]. Arq Neuropsiquiatr, 2023, 81(12): 1179-1194.
Vetrivelan R, Bandaru S S. Neural control of REM sleep and motor Atonia: Current perspectives [J]. Curr Neurol Neurosci Rep, 2023, 23(12): 907-923.
Yuan T Y, Zuo Z T, Xu J G. Neuroanatomical localization of rapid eye movement sleep behavior disorder in human brain using lesion network mapping [J]. Korean J Radiol, 2023, 24(3): 247-258.
Uemura N, Ueda J, Yoshihara T, et al. α-synuclein spread from olfactory bulb causes hyposmia, anxiety, and memory loss in BAC-SNCA mice [J]. Mov Disord, 2021, 36(9): 2036-2047.
Gao V, Briano J A, Komer L E, et al. Functional and pathological effects of α-synuclein on synaptic SNARE complexes [J]. J Mol Biol, 2023, 435(1): 167714.
Moran A K, Eiting T P, Wachowiak M. Circuit contributions to sensory-driven glutamatergic drive of olfactory bulb mitral and tufted cells during odorant inhalation [J]. Front Neural Circuits, 2021, 15: 779056.
Egger V, Kuner T. Olfactory bulb granule cells: Specialized to link coactive glomerular columns for percept generation and discrimination of odors [J]. Cell Tissue Res, 2021, 383(1): 495-506.
Abraham J N, Rawat D, Srikanth P, et al. Alpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: An update on preclinical models and therapeutic approaches [J]. Mamm Genome, 2025, 36(2): 444-464.
Abraham N M, Egger V, Shimshek D R, et al. Synaptic inhibition in the olfactory bulb accelerates odor discrimination in mice [J]. Neuron, 2010, 65(3): 399-411.
Macías-García P, Rashid-López R, Cruz-Gómez Á J, et al. Neuropsychiatric symptoms in clinically defined Parkinson’s disease: An updated review of literature [J]. Behav Neurol, 2022, 2022(1): 1213393.
Sampaio T B, Schamne M G, Santos J R, et al. Exploring Parkinson’s disease-associated depression: Role of inflammation on the noradrenergic and serotonergic pathways [J]. Brain Sci, 2024, 14(1): 100.
Miquel-Rio L, Alarcón-Arís D, Torres-López M, et al. Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy [J]. Transl Psychiatry, 2022, 12: 79.
Crowley S J, Kanel P, Roytman S, et al. Basal forebrain integrity, cholinergic innervation and cognition in idiopathic Parkinson’s disease [J]. Brain, 2024, 147(5): 1799-1808.
Jiao L W, Kang H C, Geng Y M, et al. The role of the nucleus basalis of Meynert in neuromodulation therapy: A systematic review from the perspective of neural network oscillations [J]. Front Aging Neurosci, 2024, 16: 1376764.
Björklund A, Barker R A. The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson’s disease [J]. Brain, 2024, 147(6): 1937-1952.
Jia A L, Zhang Y H, Gao H, et al. A review of Acanthopanax senticosus (Rupr and Maxim.) harms: From ethnopharmacological use to modern application [J]. J Ethnopharmacol, 2021, 268: 113586.
Zhang X D, Guan L J, Zhu L, et al. A review of the extraction and purification methods, biological activities, and applications of active compounds in Acanthopanax senticosus [J]. Front Nutr, 2024, 11: 1391601.
Fu J Q, Gao X, Lu Y, et al. Integrated proteomics and metabolomics reveals metabolism disorders in the α-syn mice and potential therapeutic effect of Acanthopanax senticosus extracts [J]. J Ethnopharmacol, 2024, 318: 116878.
Schepers J, Löser T, Behl C. Lipids and α-synuclein: Adding further variables to the equation [J]. Front Mol Biosci, 2024, 11: 1455817.
Minchev D, Kazakova M, Sarafian V. Neuroinflammation and autophagy in Parkinson’s disease-novel perspectives [J]. Int J Mol Sci, 2022, 23(23): 14997.
Sahoo S, Padhy A A, Kumari V, et al. Role of ubiquitin-proteasome and autophagy-lysosome pathways in α-synuclein aggregate clearance [J]. Mol Neurobiol, 2022, 59(9): 5379-5407.
Fu R H, Hong S Y, Chen H J. Syringin prevents 6-hydroxydopamine neurotoxicity by mediating the miR-34a/SIRT1/beclin-1 pathway and activating autophagy in SH-SY5Y cells and the Caenorhabditis elegans model [J]. Cells, 2023, 12(18): 2310.
Lu Y, Gao X, Nan Y, et al. Acanthopanax senticosus Harms improves Parkinson’s disease by regulating gut microbial structure and metabolic disorders [J]. Heliyon, 2023, 9(7): e18045.
Li M, Luo Q, Tao Y Y, et al. Pharmacotherapies for drug-induced liver injury: A current literature review [J]. Front Pharmacol, 2022, 12: 806249.
张正一, 李廷利, 王艳艳, 等. 刺五加对大鼠睡眠-觉醒节律的影响及脑内GABA、L-Glu含量变化的研究[J]. 中医药学报, 2022, 50(8): 17-21.
Liu H D, Yang L, Wan C L, et al. Exploring potential mechanism of Ciwujia Tablets for insomnia by UPLC-Q-TOF-MS/MS, network pharmacology, and experimental validation [J]. Front Pharmacol, 2022, 13: 990996.
Cheng C Z, Xie M Z, Tian Y, et al. Insomnia treatment based on the regulation of the GABAergic system: Traditional Chinese medicine perspectives and therapeutic approaches [J]. Front Neurosci, 2026, 19: 1670273.
Zheng Q, Lu Y, Yu D H, et al. Spatial metabolomics reveals the effects of Acanthopanax senticosus on region-specific alterations in neurotransmitters and metabolites levels in the brains of α-syn transgenic Parkinson’s disease model mice [J]. Metab Brain Dis, 2025, 40(8): 290.
Guo M Y, Pan J, Li M M, et al. New anti-neuroinflammatory triterpenoid saponins from the leaves of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim [J]. Fitoterapia, 2025, 183: 106538.
Rukavina K, Batzu L, Leta V, et al. New approaches to treatments for sleep, pain and autonomic failure in Parkinson’s disease - Pharmacological therapies [J]. Neuropharmacology, 2022, 208: 108959.
Wang H L, Liu Y M, Zhao J Y, et al. Possible inflammatory mechanisms and predictors of Parkinson’s disease patients with fatigue (Brief Review) [J]. Clin Neurol Neurosurg, 2021, 208: 106844.
Xu H J, Zheng X L, Xing X Y, et al. Advances in autonomic dysfunction research in Parkinson’s disease [J]. Front Aging Neurosci, 2025, 17: 1468895.
Kos G, Czarnek K, Sadok I, et al. Eleutherococcus senticosus (Acanthopanax senticosus): An important adaptogenic plant [J]. Molecules, 2025, 30(12): 2512.
Tan A H, Lim S Y, Lang A E. The microbiome-gut-brain axis in Parkinson disease: From basic research to the clinic [J]. Nat Rev Neurol, 2022, 18(8): 476-495.
Lei Q C, Wu T T, Wu J, et al. Roles of α-synuclein in gastrointestinal microbiome dysbiosis-related Parkinson’s disease progression (Review) [J]. Mol Med Rep, 2021, 24(4). DOI:10.3892/mmr.2021.12374.
Li X J, Chen C, Leng A J, et al. Advances in the extraction, purification, structural characteristics and biological activities of Eleutherococcus senticosus polysaccharides: A promising medicinal and edible resource with development value [J]. Front Pharmacol, 2021, 12: 753007.
Wang T N, Li S Y, Fann L Y, et al. Neuroprotective potential of isofraxidin: Alleviating Parkinsonian symptoms, inflammation and microglial activation [J]. J Cent Nerv Syst Dis, 2025, 17: 11795735241312661.
Yao Y, Liao C Y, Qiu H H, et al. Effect of eleutheroside E on an MPTP-induced Parkinson’s disease cell model and its mechanism [J]. Molecules, 2023, 28(9): 3820.
Zhou Y, Li X T, Chen P P, et al. Eleusenticosides A—O: Neuroprotective triterpenoid saponins from the leaves of Eleutherococcus senticosus using a building-block-based molecular networking strategy [J]. J Nat Prod, 2025, 88(10): 2416-2436.

2026年第57卷第19期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501j.issn.0253-2670.2026.19.031

接收时间：2026-04-10
首发时间：2026-10-29

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2026-04-10

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501j.issn.0253-2670.2026.19.031

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT